---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-025661"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2022-02-22T23:59:59+00:00"
generated_at: "2026-06-27T05:59:46.264277+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Protagonist Therapeutics increases inducement plan share reserve by 500,000 shares

## Summary
- Compensation Committee approved amendment to 2018 Inducement Plan on Feb 15, 2022, adding 500,000 shares (total 1,750,000).
- New shares reserved exclusively for inducement grants to new employees not previously employed by the company.
- Amendment adopted without stockholder approval under Nasdaq Rule 5635(c)(4) for inducement awards.

## SEC filing metadata
- accession: 0001104659-22-025661
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2022-02-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465922025661/0001104659-22-025661-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465922025661/tm227311d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-025661
- JSON: https://secwatch.observer/filing/0001104659-22-025661.json
- Plain text: https://secwatch.observer/filing/0001104659-22-025661.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.